הכנסה תפעולית לפני ניכוי פחת: Trinity Biotech plc (TRIB)

The efficiency of Trinity Biotech plc (TRIB) is based on strict control over reagent supplies through pharmacy chains. Growth is driven by the implementation of CGM systems and new insurance codes in the US. However, debt load and slow scaling create liquidity shortage risks. The GURU.Markets portal features a chart of absolute EBITDA dynamics, where the current level is around 0.00, allowing for a real-time assessment of the cash result from core operations.

This metric reflects the actual cash flow from the core operations of Trinity Biotech (TRIB), adjusted for depreciation and taxes, which confirms the monetization of long-term contracts within the diagnostics segment. By analyzing the EBITDA chronology, an investor can see the resilience of operating profit, supported by high barriers to entry and FDA/CE regulatory protection, allowing market volatility to be decoupled from the fundamental value of the business.